Back to list

CH3 Affinity Resin: CH3 Domain Capture

Published on November 12, 2026

CH3 Affinity Resin: CH3 Domain Capture

Figure 1: The CH3 constant domain



Abstract: The CH3 (VHH) affinity resin captures the CH3 constant domain of Fc. It is independent of CH2 glycosylation and of the classic Protein A epitope, so it can purify Fc-missing constructs, engineered Fc variants, and certain bispecific antibodies that are missed by Protein A workflows.


1. Position of CH3 in the IgG molecule

The IgG heavy chain carries three constant domains: CH1, CH2, and CH3. CH1 sits on the Fab arm, close to the antigen-binding variable region; CH2 and CH3 together form the Fc. CH3 is the C-terminal constant domain, located at the tail of the Fc. This position matters: it is far from the antigen-binding site, so a CH3 ligand does not interfere with antigen recognition.


2. Why choose CH3

The strength of an affinity resin depends on the “epitope” it binds. The classic choice, Protein A, recognizes Fc through a site that overlaps the CH2–CH3 interface (some subclasses also involve the VH3 domain). This works well for most conventional IgGs, but once the Fc is modified, it becomes a bottleneck.

CH3 is a more “forgiving” target, for three reasons:

· Conserved. CH3 is stable across IgG subclasses, so a single ligand can capture a broad spectrum of antibodies.

· Structurally distinct. CH3 is a well-folded, exposed domain, giving the ligand a clean, reproducible interface.

· Glycosylation-independent. CH3 does not require the N-linked glycan on CH2, so it is compatible with deglycosylated antibodies, engineered Fc variants, and Fc fusion proteins — whereas glycan-dependent steps can fail on these constructs.

When the Fc itself has been altered, you need a handle on a “non-classical Fc epitope.”


3. Why use a VHH single-domain antibody as the ligand

Protein A and Protein G are bacterial proteins; VHH, a heavy-chain-only antibody domain, is another type of ligand. It is only about one-tenth the size of a conventional antibody, has no light chain, and can be recombinantly expressed in microorganisms, making it easy to engineer: small, stable, and tunable for high alkali resistance and high target specificity.

Matwings Technology’s Nexligos™ CH3 (VHH) follows this approach. The VHH ligand is engineered to recognize the CH3 constant domain with high specificity, and the resulting resin binds CH3 tightly while tolerating the cleaning conditions used in GMP purification — rather than relying on the broad Fc binding of bacterial proteins.


4. How the CH3 affinity resin works in the process

The CH3 resin follows the “capture–elute” logic of any affinity resin, but binding is driven by the CH3 domain.

· Bind. The CH3-recognizing ligand is coupled to a bead matrix; as clarified feed flows through, antibodies are captured via the CH3 domain.

· Wash. Loose host-cell protein, DNA, and resin components are washed away.

· Elute. Antibodies are released and collected under mild conditions.

· CIP regeneration. Alkaline cleaning prepares the resin for the next cycle.

 

CH3 capture process.

Figure 2: Working flow of the CH3 affinity resin in the process


5. Quick comparison of CH3 vs CH1 vs Protein A

 

CH3 (VHH)

CH1 (VHH)

Protein A

Recognition site

Fc, CH3 constant domain

Fab, CH1 constant domain

Fc (CH2–CH3 interface / VH3)

Main molecules

Fc-containing intact IgG, Fc fusions, engineered Fc

Fab-containing intact IgG

Conventional Fc-binding IgG

When suitable

Fc modified, deglycosylated, or engineered

Want to capture via the Fab arm

Target is standard full-length IgG

Caveats

CH3 masked or not exposed

CH1 unreachable in this format

Fc-missing, deglycosylation-sensitive, some engineered Fc, certain bispecifics

 

Resin selection by molecule type.

Figure 3: Selecting capture resin by molecule type (CH3 / CH1 / Protein A / Protein L)


6. Three common misconceptions

· “CH3 resin is just a Protein A replacement.” No. CH3 capture is a complementary handle for Fc-modified formats; standard full-length IgG may still be captured first with Protein A.

· “Dynamic binding capacity alone is enough.” Capacity without context (breakthrough ratio, residence time, and the actual feed) tells you little. Compare figures on the same basis.

· “Media lifetime is only about binding.” CIP, cycling, and initial capacity matter equally; a resin that withstands alkaline cleaning lasts longer than one that only binds.


7. Product description

Nexligos™ CH3 (VHH) by Matwings Technology is a VHH single-domain antibody affinity resin that captures the CH3 constant domain of the heavy chain. It is designed for formats that conventional Fc-binding resin cannot easily capture: Fc-missing constructs, engineered Fc variants, and bispecific antibodies. For procurement, see the Nexligos™ CH3 affinity resin supplier guide, or the VHH affinity resin product page.


9. FAQ

Q1: What is the relationship between CH3 and Fc?

CH3 is a constant domain that, together with CH2, forms the Fc; it is located at the C-terminus.

Q2: Can the CH3 resin purify Fc fusion proteins?

In principle, yes, as long as the Fc fusion exposes an accessible CH3 domain. Because CH3 capture does not depend on CH2 glycosylation, it suits constructs where the classic Fc epitope is unavailable or engineered away.

Q3: Can it replace Protein A? 

Not a universal replacement. It is a complementary handle; for standard full-length IgG, it depends on the molecule, the feed, and the purification goal.

Q4: How do I confirm binding specificity?

Ask the supplier for binding data — ideally the specificity/cross-reactivity studies in the batch release report — and confirm the claimed recognition site against your construct before committing.


Scan to join community

Scan to join community